NCT05740566 – A Randomized, Open-label, Phase 3 Study of Tarlatamab Compared with Standard of Care in Subjects with Relapsed Small Cell Lung Cancer after Platinum-based First-line Chemotherapy (DeLLphi-304)
The main objective is to compare the efficacy of tarlatamab with standard of care (SOC) on prolonging overall survival (OS).